References
- Abstracts of the 6th Congress of the European Association of Dermatologic Oncology 16–19 June 2010, Athens, Greece. Melanoma Res.20(Suppl.), e1–e91 (2010).
- Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr. Opin. Oncol.22, 178–183 (2010).
- Leachman SA, Carucci J, Kohlmann W et al. Selection criteria for genetic assessment of patients with familial melanoma. J. Am. Acad. Dermatol.61, 677.e1–e14 (2009).
- Ji S, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol. Aspects Med.31, 194–204 (2010).
- Schrerer D, Rachakonda PS, Angelini S et al. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. J. Invest. Dermatol. DOI: 10.1038/jid.2010.242 (2010) (Epub ahead of print).
- Hersey P, Bastholt L, Chiarion-Sileni V et al. Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol.20(Suppl. 6), vi35–vi40 (2009).
- Newton-Bishop JA, Beswick S, Randerson-Moor J et al. Serum 25-hydroxy vitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J. Clin. Oncol.27, 5439–5444 (2009).
- Pellacani G, Scope A, Ferrari B et al. New insights into nevogenesis: in vivo characterization and follow-up of melanocytic nevi by reflectance confocal microscopy. J. Am. Acad. Dermatol.61, 1001–1013 (2009).
- Gershenwald JE, Soong SJ, Balch CM. American Joint Committee on Cancer (AJCC), Melanoma Staging Committee. 2010 TNM staging system for cutaneous melanoma…and beyond. Ann. Surg. Oncol.17, 1475–1477 (2010).
- Marsden JR, Newton-Bishop JA, Burrows L et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br. J. Dermatol.163, 238–256 (2010).
- Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354, 709–718 (2006).
Websites
- 7th EADO Congress www.eado2011.com
- Melanoma Researchhttp://journals.lww.com/melanomaresearch/pages/default.aspx